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The Spanish influenza pandemic swept the globe in
the autumn and winter of 1918-19, and resulted in the
deaths of approximately 40 million people. Clinically, epi-
demiologically, and pathologically, the disease was remark-
ably uniform, which suggests that similar viruses were
causing disease around the world. To assess the homo-
geneity of the 1918 pandemic influenza virus, partial
hemagglutinin gene sequences have been determined for
five cases, including two newly identified samples from
London, United Kingdom. The strains show 98.9% to
99.8% nucleotide sequence identity. One of the few differ-
ences between the strains maps to the receptor-binding
site of hemagglutinin, suggesting that two receptor-binding
configurations were co-circulating during the pandemic.
The results suggest that in the early stages of an influenza
A pandemic, mutations that occur during replication do not
become fixed so that a uniform “consensus” strain circu-
lates for some time. 
T
he 1918–19 influenza pandemic began, in some parts
of the world, with mild outbreaks in the spring of
1918. In the fall of that year, a lethal wave swept the globe.
Outbreaks occurred in early September in North America,
Europe, and Africa and spread rapidly, so that the disease
had peaked and declined worldwide by the end of
December (1–4). Many areas had an additional wave of the
disease in the early months of 1919. In most communities,
the fall wave of the pandemic lasted approximately l
month, with 25% to 30% of the population experiencing
symptomatic disease. Clinically, epidemiologically, and
pathologically, the disease was remarkably uniform, sug-
gesting that similar viruses were causing disease world-
wide (5). To assess the homogeneity of the 1918 pandem-
ic influenza virus, partial hemagglutinin (HA) gene
sequences were determined for strains from five cases,
including two newly identified samples from London,
United Kingdom. The strains show 98.9% to 99.8%
nucleotide sequence identity. One of the few differences
between the strains maps to the receptor-binding site of
HA, which suggests that two receptor-binding configura-
tions were co-circulating during the pandemic.
Influenza A virus is capable of rapid genetic change in
mammals (6–8). Its polymerase complex lacks proofread-
ing capability, such that one in five virus particles pro-
duced is likely to contain a change at one of its approxi-
mately 13,500 nt (9). If such a change provides the virus
with a competitive advantage, that strain quickly replaces
its predecessor. In humans, the need to escape preexisting
immunity exerts positive selection pressure on changes in
amino acids comprising the antigenic sites of the surface
glycoproteins, HA and neuraminidase (NA) (6,10). The
process of progressive change in the antigenic properties
of the virus is called antigenic drift and results in the emer-
gence of an antigenically distinct variant strain every 2–3
years. Between drift epidemics, the influenza virus appears
to be antigenically uniform (11), but the degree of genetic
uniformity has not been studied extensively. 
In pandemic influenza, one or both of the virus’s sur-
face proteins are replaced with proteins to which the
human population has no preexisting immunity (6,12). The
virus then spreads explosively, producing symptomatic
infection in up to one third of most populations. During the
rapid initial spread of a pandemic strain, little antigenic
pressure on the virus exists. One might expect the genetic
structure under these circumstances to be relatively con-
stant. However, the degree of genetic identity among viral
isolates during a pandemic is not known. Very few full-
length HAsequences of viruses from the peaks of the 1957
and 1968 pandemics are available, and all of these viruses
had been grown at least once in eggs before sequencing—
a process that can select for an unpredictable number of
sequence changes (13,14). Therefore, this study represents
an initial attempt to measure the degree of genetic homo-
geneity of a pandemic virus. Since the sequences have
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Materials and Methods
Patients and Samples
The genetic sequences encoding the HA1 domains of
three 1918 influenza strains have been determined (15,16).
Two of the strains came from U.S. soldiers who died on
September 26, 1918: one in Camp Upton, New York, and
one in Fort Jackson, South Carolina. The third came from
an Inuit woman who died in mid-November 1918 in a
remote village on the Seward Peninsula of Alaska. 
To obtain further samples for analysis, we examined
autopsy material of 14 patients who died in the fall and
winter of 1918 to 1919. The material consisted of forma-
lin-fixed, paraffin-embedded tissues, stained slides, and
clinical records from the files of the Morbid Anatomy
Department of the Royal London Hospital. The cases were
preselected by histologic criteria for further analysis, and
samples were taken from patients who died from acute
influenza after clinical courses of <1 week (16–18). Of
these 14 lung samples, 4 were positive for influenza RNA
on subsequent molecular genetic analysis, but only 2 had
sufficient material for HA1 sequencing. The first patient
was a 50-year-old woman admitted to the hospital on
November 12, 1918, with influenza and pneumonia. She
died on November 13. The postmortem diagnosis was
bronchopneumonia. The second patient was a 25-year-old
man admitted to the hospital on February 13, 1919. He
died on February 15 of influenza. The postmortem diagno-
sis was lobar pneumonia with toxemia.
Methods
Sample preparation, reverse transcription, polymerase
chain reaction (PCR), and sequencing were performed as
described previously (15). (Primers used are available
upon request.) PCR was performed from at least two sep-
arate reverse transcription reactions, and products from at
least two PCR reactions were sequenced in each case to
ensure accuracy and exclude amplification artifacts.
Sequences used to evaluate the complexity of pandemic
and epidemic influenza strains were obtained from the
Influenza Sequence Database (available from: URL:
http://www.flu.lanl.gov/).
Results
The 563-bp fragments sequenced for this study, encod-
ing the antigenic and receptor-binding sites of the HA1
domain (19–21), represent the most variable portion of the
influenza genome (Figure). The London cases were desig-
nated A/London/1/1918 (H1N1) and A/London/1/1919
1250 Emerging Infectious Diseases • Vol. 9, No. 10, October 2003
RESEARCH
Figure. Partial HA1 domain cDNA sequences from five
1918-19 cases. A 563-bp fragment encoding antigenic
(19,20) and receptor-binding (21) sites of the HA1
domain is shown, with the sequences aligned to
A/Brevig Mission/1/1918 (BREVIG18) (15). Dots repre-
sent sequence identity as compared to BREVIG18. The
numbering of the nucleotide sequence is aligned to
A/PR/8/1934 (GenBank accession no. NC_002017)
and refers to the sequence of the gene in the sense
(mRNA) orientation. The partial HA1 translation product
for BREVIG18 is shown above its cDNA sequence.
Amino acid numbering is aligned to the H3 HA1 domain
(15). Boxed amino acids indicate potential glycosylation
sites as predicted by the sequence (15). Residues that
have been shown experimentally to affect receptor-
binding specificity in H1 HAs, D77, A138, P186, D190,
L194, and D225 (21–23) are indicated by a ( symbol
above these six residues. Residues defining four anti-
genic sites are indicated: Cb (#), Sa (!), Sb ("), and
Ca (%) (19,20). Residues that have been mapped to
both receptor-binding and antigenic sites (positions 194
and 225) are marked with two symbols. When a
nucleotide change as compared to BREVIG18 results in
a changed amino acid, the resultant amino acid is
shown in lower case to the right of the BREVIG18
residue. Strain abbreviations and GenBank accession
numbers: A/Brevig Mission/1/1918 (BREVIG18, #
AF116575), A/South Carolina/1/1918 (SC18, #
AF117241), A/New York/1/1918 (NY18, # AF116576),
A/London/1/1918 (LONDON18, # AY184805), and
A/London/1/1919 (LONDON19, # AY184806).(H1N1). These two sequences, when compared to the three
previously sequenced North American strains (15), differ
from each other by 1 nt to 3 nt, showing a sequence iden-
tity of 98.9% to 99.8%. 
A/London/1/1918 shows 2 nt differences, compared to
A/Brevig Mission/1/1918, one of which would change the
amino acid at codon 188 from G to S (amino acid number-
ing is aligned to the H3 influenza HA). This residue is near
several of the residues that have been shown experimental-
ly to affect receptor-binding specificity of H1 HAs (21–23)
and next to one of the mapped Sb antigenic site residues
(19,20). A/London/1/1919 shows 3 nt differences from
A/Brevig Mission/1/1918, 2 of which are nonsynonymous,
resulting in changes of V223I and D225G. The V223I
change is near Ca antigenic site residues, and the D225G
change is at a residue that functions both in receptor-bind-
ing and as a Ca antigenic site residue. Amino acid 225 also
varies among North American strains; A/New
York/1/1918, like A/London/1/1919, has a glycine at posi-
tion 225, as do most avian influenza strains. A/South
Carolina/1/1918 and A/Brevig Mission/1/1918, like
A/London/1/1918 and most subsequent human H1 strains,
have aspartic acid at this position (Figure) (15). The rela-
tive genetic homogeneity of the 1918–19 isolates encour-
aged us to analyze sequences from the 1957 and 1968 pan-
demics.
GenBank contains complete HA1 domain–encoding
sequences for eight 1957 H2N2 strains. As noted in previ-
ous studies of receptor-binding specificity (22,24), the
1957 strains have undergone varying passage histories, but
all have been passed at least once. Three of the strains have
been sequenced more than once and differ by as many as 8
nt within the same strain. Between sequences, the number
of nucleotide differences ranges from only 1 nt difference
between A/Chile/6/1957 and A/Davis/1/1957 to 12 differ-
ences between one of the A/Japan/305/1957 sequences and
one of the A/Singapore/1/1957 sequences. Overall, the
sequences show 98.9% to 99.9% identity at the nucleotide
level, and 98.5% to 100% identity at the amino acid level.
More limited sequence data are available for the 1968
H3N2 pandemic strains. The complete HA1 domain
sequence is available for only three strains, two of which
have been sequenced twice each. The two
A/NT/60/68/29C sequences differ by 4 nt. The most diver-
gent sequences differ by 24 nt (A/NT/60/68/29C vs.
A/Hong Kong/1/68), thus showing 97.6% to 100% identi-
ty between sequences at the nucleotide level, and 96.0% to
100% identity at the amino acid level.
Studies from epidemic years have yielded similar
results. A 2001 study (25) examined variation in the HA
gene of human H3N2 viruses in Spain from 1996 to 2000.
During this time, strains antigenically similar to
A/Wuhan/359/1995 were replaced by strains similar to
A/Sydney/5/1997 and then by strains similar to
A/Panama/2007/1999. Within the groups of viruses
belonging to each antigenic group, sequence variation was
minimal. For example, among the viruses that reacted anti-
genically with Sydney, but not Panama and Wuhan, 2–10
nt differences occurred over the 591 nt sequenced (98.3%
to 99.7% identity). 
An unpublished study provides sequences of the HA1
domain of the H3-subtype HA of 16 A/Sydney/05/1997-
like (H3N2) influenza virus isolates circulating in Canada
during the 1997/98 influenza epidemic season (GenBank
no. AF087700–AF087702, AF087707, AF087708,
AF096306–AF096316) (26). Two of the isolates had iden-
tical sequences, while the others varied by 1 nt to 14 nt
over 981 nt (98.6% to 100% identity). 
Discussion
The three North American 1918 influenza strains
sequenced previously were isolated from patients separat-
ed by nearly 2 months in time and almost 4,000 miles in
distance (27). Two nucleotide differences were found
among these three strains, one of which resulted in an
amino acid substitution in the receptor-binding site (15).
All three cases likely derived from the initial introduction
of the fall wave into the United States, believed to have
occurred in Boston in early September 1918. The virus
then spread rapidly from Camp Devens, Massachusetts,
the first U.S. army base to experience the epidemic, which
then reached army bases throughout the eastern United
States within 2 weeks (2). Influenza probably reached
Brevig Mission, Alaska, via Seattle, Washington. The pan-
demic reached Camp Lewis, Washington, in mid-
September, following the arrival of a troop ship from
Philadelphia, Pennsylvania (1,2), and spread to Seattle by
late September. After careful screening to exclude sick
passengers, a ship left Seattle for Nome, Alaska, in mid-
October, but days after its arrival local residents began
falling ill (1). An account of the pandemic as it occurred in
Brevig Mission reports that visitors from Nome brought
the disease to the village in November (28). This chain of
events suggests that the Alaskan outbreak was not the
result of a separate introduction of the 1918 influenza from
Asia to the West Coast of the United States. 
The spring wave of the 1918 epidemic was widespread
in France and Spain during April and May but did not
reach England until June. The fall wave also arrived some-
what later in England than in continental Europe and the
United States; peak mortality in London occurred during
the first 2 weeks of November (2). Asecond peak occurred
in the third week of February 1919. One strain from each
of these peaks was sequenced for this study.
Our results show that strains separated by over 7,500
miles (Brevig Mission, Alaska, to London, United
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February 15, 1919) share a sequence identity of 99%. This
level of genetic homogeneity is slightly higher than that
seen for the available 1957 and 1968 pandemic strains, but
the 1957 and 1968 strains were not sequenced directly
from clinical material. Sequences from different passages
of the same strain were sometimes as different from each
other as they were from other strains (29), suggesting that
sequence heterogeneity observed was the result of culture
adaptation, making it impossible to determine how homo-
geneous the pandemic viruses actually were. Even so, the
1957 and 1968 pandemic strains show >97% identity
between strains. Similar levels of genetic homogeneity
were seen in strains from case-patients isolated from a drift
epidemic in 1997. Thus, influenza viruses circulating dur-
ing a single outbreak, whether epidemic or pandemic,
show levels of sequence identity consistent with the uni-
formity of the 1918 cases. 
Despite the uniformity of the 1918 strains, one of the
variable sites is an amino acid known to be important in
receptor binding (21). At a subset of amino acids critical
for receptor binding, avian strains differ from swine H1s at
only one amino acid, E190D (15). At these amino acids,
two of the cases (A/New York/1/1918 and
A/London/1/1919) are identical to that of A/sw/
Iowa/1976/31 (a classical swine strain). The other 1918
cases have an additional change from the avian consensus
at amino acid 225. Since swine viruses with the same
receptor site as A/sw/Iowa/1976/31 bind both SAα2,3Gal
and SAα2,6Gal (14), A/New York/1/1918 and
A/London/1/1919 probably also had the capacity to bind
both receptors. Because two of five 1918-19 analyzed fall
wave strains from case-patients have the swine-like recep-
tor-binding pattern, the E190D change alone is apparently
sufficient to allow viral replication in the human respirato-
ry tract. However, the existence of three strains with the
additional G225D change shows that both receptor-bind-
ing variants were co-circulating throughout the pandemic.
The current evidence does not suggest progression from
one receptor-binding pattern to the other during the pan-
demic, since the two variants are present, on both conti-
nents, both early and late in the pandemic. Since residue
225 has also been identified as part of the Ca antigenic site
(19), the co-circulating strains possibly differed in anti-
genic reactivity as well as receptor-binding characteristics.
This study is the first to examine the genetic homogene-
ity of a pandemic influenza virus directly from clinical
material. The results suggest that in the early stages of a
pandemic, mutations that occur during replication do not
become fixed so that a uniform consensus strain circulates
for some time. Studies of influenza strains circulating after
1919 should provide insight into how pandemic viruses
evolve after the initial waves through immunologically
vulnerable populations. In terms of pandemic planning,
our results indicate that a specific antiviral drug or vaccine
would have a uniform effect during the important and
often lethal first wave of a pandemic (30,31).
This work was supported by a grant from the National
Institute of Allergy and Infectious Diseases (R01 AI50619-01) to
J.K.T. and by the intramural funds of the Armed Forces Institute
of Pathology. J.S.O., C.L.B., and R.S.D. gratefully acknowledge
financial support from the Wellcome Trust and the Ian Heap fund.
Ms. Reid is a research biologist in the Molecular Pathology
Division at the Armed Forces Institute of Pathology. Her princi-
pal research interest is pandemic influenza. 
References
1. Crosby A. America’s forgotten pandemic. Cambridge: Cambridge
University Press; 1989.
2. Jordan E. Epidemic influenza: a survey. Chicago: American Medical
Association; 1927.
3. Reid AH, Taubenberger JK, Fanning TG. The 1918 Spanish influen-
za: integrating history and biology. Microbes Infect 2001;3:81–7.
4. Taubenberger JK, Reid AH, Janczewski TA, Fanning TG. Integrating
historical, clinical and molecular genetic data in order to explain the
origin and virulence of the 1918 Spanish influenza virus. Philos Trans
R Soc Lond B Biol Sci 2001;356:1829–39.
5. Patterson KD, Pyle GF. The geography and mortality of the 1918
influenza pandemic. Bull Hist Med 1991;65:4–21.
6. Wright PE, Webster RG. Orthomyxoviruses. In: Knipe DM, Howley
PM, editors. Fields virology. Vol 1. Philadelphia: Lippincott Williams
and Wilkins; 2001:1533–79.
7. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y.
Evolution and ecology of influenza A viruses. Microbiol Rev
1992;56:152–79.
8. Lamb RA, Takeda M. Death by influenza virus protein. Nat Med
2001;7:1286–8.
9. Parvin JD, Smith FI, Palese P. Rapid RNA sequencing using double-
stranded template DNA, SP6 polymerase, and 3'-deoxynucleotide
triphosphates. DNA. 1986;5:167–71.
10. Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human
influenza viruses. Philos Trans R Soc Lond B Biol Sci
2001;356:1861–70.
11. Centers for Disease Control and Prevention. Influenza summary
update: 2001–2 influenza season summary. June 10, 2002. [Accessed
September 23, 2002]. Available from: URL: http://www.cdc.gov/nci-
dod/diseases/flu/weeklyarchives/01-02summary.htm 
12. Kilbourne E. Influenza pandemics in perspective. JAMA
1977;237:1225–8.
13. Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-
cell selection of influenza virus antigenic variants. Nature
1983;303:706–9.
14. Gambaryan A, Tuzikov A, Piskarev V, Yamnikova SS, Lvov DK,
Robertson JS, et al. Specification of receptor-binding phenotypes of
influenza virus isolates from different hosts using synthetic sialylgly-
copolymers: non-egg-adapted human H1 and H3 influenza A and
influenza B viruses share a common high binding affinity for 6'-sia-
lyl(N-acetyllactosamine). Virology 1997;232:345–50.
15. Reid AH, Fanning TG, Hultin JV, Taubenberger JK. Origin and evo-
lution of the 1918 “Spanish” influenza virus hemagglutinin gene.
Proc Natl Acad Sci U S A 1999;96:1651–6.
1252 Emerging Infectious Diseases • Vol. 9, No. 10, October 2003
RESEARCH16. Taubenberger JK, Reid AH, Krafft AE, Bijwaard KE, Fanning TG.
Initial genetic characterization of the 1918 “Spanish” influenza virus
[see comments]. Science. 1997;275:1793–6.
17. Winternitz MC, Wason IM, McNamara FP. The pathology of influen-
za. New Haven (CT): Yale University Press; 1920.
18. Wolbach SB. Comments on the pathology and bacteriology of fatal
influenza cases, as observed at Camp Devens, Mass. Johns Hopkins
Hospital Bulletin 1919;30:104.
19. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic
structure of the influenza virus A/PR/8/34 hemagglutinin (H1 sub-
type). Cell 1982;31:417–27.
20. Raymond F, Caton A, Cox N, Kendal AP, Brownlee GG. The anti-
genicity and evolution of influenza H1 haemagglutinin, from
1950–57 and 1977–1983: two pathways from one gene. Virology
1986;148:275–87.
21. Matrosovich M, Gambaryan A, Teneberg S, Piskarev VE, Yamnikova
SS, Lvov DK, et al. Avian influenza A viruses differ from human
viruses by recognition of sialyloigosaccharides and gangliosides and
by a higher conservation of the HA receptor-binding site. Virology
1997;233:224–34.
22. Rogers G, D’Souza B. Receptor binding properties of human and ani-
mal H1 influenza virus isolates. Virology 1989;173:317–22.
23. Matrosovich MN, Gambaryan AS, Tuzikov AB, Byramova NE,
Mochalova LV, Golbraikh AA, et al. Probing of the receptor-binding
sites of the H1 and H3 influenza A and influenza B virus hemagglu-
tinins by synthetic and natural sialosides. Virology 1993;196:111–21.
24. Matrosovich M, Tuzikov A, Bovin N, Gambaryan A, Klimov A,
Castrucci MR, et al. Early alterations of the receptor-binding proper-
ties of H1, H2, and H3 avian influenza virus hemagglutinins after
their introduction into mammals. J Virol 2000;74:8502–12.
25. Coiras MT, Aguilar JC, Galiano M, Carlos S, Gregory V, Lin YP, et
al. Rapid molecular analysis of the haemagglutinin gene of human
influenza A H3N2 viruses isolated in Spain from 1996 to 2000. Arch
Virol 2001;146:2133–47.
26. Macken C, Lu H, Goodman J, Boykin L. The value of a database in
surveillance and vaccine selection. In: Osterhaus A, Cox N, Hampson
A, editors. Options for the control of influenza IV. Amsterdam:
Excerpta Medica; 2001. p. 103–6.
27. Reid AH, Taubenberger JK. The 1918 flu and other influenza pan-
demics: “over there” and back again. Lab Invest 1999;79:95–101.
28. Fosso C. Alone with death on the Tundra. In: Hedin R, Holthaus G,
editors. Alaska: Reflections on land and spirit. Tucscon (AZ):
University of Arizona Press; 1989. p. 215–22.
29. Connor R, Kawaoka Y, Webster R, Paulson J. Receptor specificity in
human, avian, and equine H2 and H3 influenza virus isolates.
Virology 1994;205:17–23.
30. Gensheimer KF, Fukuda K, Brammer L, Cox N, Patriarca PA, Strikes
RA. Preparing for pandemic influenza: the need for enhanced surveil-
lance. Vaccine 2002;20(Suppl 2):S63–5.
31. Hayden FG. Perspectives on antiviral use during pandemic influenza.
Philos Trans R Soc Lond B Biol Sci 2001;356:1877–84.
Address for correspondence: Jeffery K. Taubenberger, Armed Forces
Institute of Pathology, Department of Cellular Pathology and Genetics,
1413 Research Blvd., Building 101, Room 1057, Rockville, MD 20850-
3125, USA; fax: 1-301-295-9507; email: taubenbe@afip.osd.mil
Emerging Infectious Diseases • Vol. 9, No. 10, October 2003 1253
RESEARCH